Mercedes Robledo is the head of the Hereditary Endocrine Cancer Group, in the Human Genetics Cancer Program at the Spanish National Cancer Center (CNIO), Madrid, Spain.

Her group has made substantial contribution to understanding the genetic bases of endocrine tumours, identifying two new genes involved in hereditary pheochromocytomas and paragangliomas, and genes responsible for part of the hidden heritability of follicular cell derived thyroid carcinomas. Her research has been supported by the FP7-HEALTH program of the European Commission, Paradifference Foundation, Spanish Ministry of Health, Autonomous Community of Madrid, Spanish Fundación Mutua Madrileña, and GETNE (Grupo Español de Tumores Neuroendocrinos).

Over the last years, she has established strategic collaborations with Hospitals and Clinical Groups for the study of endocrine and neuroendocrine tumours related to rare diseases (Von Hippel-Lindau disease, Pheochromocytoma and Paraganglioma, Multiple Endocrine Neoplasia type 1 and 2, etc). These National networks, together with key collaborations with international groups have been instrumental for our studies to identify new major susceptibility genes related to the development of these tumours, as well as predictive diagnostic and prognostic markers of utility in the clinical setting. In fact, her group is a referral Center for the study of these diseases. The current H-index (WOK) of Dr Robledo is 38, based on 181 papers. The 57% of the most cited papers are led by members of her team.
She was co-chair of the Pheochromocytoma-Paraganglioma Research Support Organization (PRESSOR), from 2012 to 2014, and currently she is member of the ENS@T Steering Committee (European Network for the Study of adrenal Tumours). Member of the European Network for the Study of Adrenal Tumors (ENS@T), and of the Spanish Society of Human Genetics. Mercedes Robledo received the International Medal 2016 awarded by the Society for Endocrinology.